{"product_id":"sybx-swot-analysis","title":"(SYBX) Synlogic, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Reference Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Synlogic, Inc. SWOT Analysis gives a concise, company-specific view of strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions; the content shown here is a real preview of the product so you can judge style and substance before buying—purchase the full version to download the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e5 clinical-stage programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSynlogic’s 5 clinical-stage programs give it a broader shot on goal than a single-asset biotech. The pipeline spans metabolic and immunological diseases, including 5 named synthetic biotic candidates, so one setback does not derail the whole platform. That mix also shows Synlogic is building a repeatable development engine, not just advancing one lead program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 Phase II PKU assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1618 and SYNB1934 are both in Phase II for phenylketonuria, giving Synlogic, Inc. two shots at the same rare-disease market. That creates internal validation for the platform and may raise the odds of finding a useful profile across patient subgroups. PKU is also biomarker-driven, with blood phenylalanine levels giving a clear readout for response.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 oral non-systemic therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSynlogic, Inc. has 4 oral, non-systemically absorbed programs: SYNB1618, SYNB1934, SYNB1353, and SYNB8802. This local-acting design can help support a safer profile than injected or infused drugs, while making daily use simpler for chronic metabolic diseases that need repeat treatment. Oral dosing also lowers patient burden and can improve adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e2 strategic partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic's 2 strategic partnership pillars, with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc., give it validation from established life science names and reduce the need to build every capability in-house.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoche adds technical and development depth\u003c\/li\u003e\n\u003cli\u003eGinkgo adds synthetic biology know-how\u003c\/li\u003e\n\u003cli\u003ePartners can widen future commercialization paths\u003c\/li\u003e\n\u003cli\u003eExecution risk is shared, not solo\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters for a small biotech, where outside support can cut cost, speed development, and improve credibility with regulators and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCambridge, Massachusetts base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic, Inc.'s Cambridge, Massachusetts base is a real edge because it sits in one of the strongest biotech clusters in the U.S. The area gives the company direct access to Harvard, MIT, top hospitals, scientists, and venture capital, which helps hiring, research ties, and partnership talks. For a clinical-stage company, that kind of dense ecosystem can shorten recruiting time and make business development easier.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop biotech talent pool\u003c\/li\u003e\n\u003cli\u003eClose to major research institutions\u003c\/li\u003e\n\u003cli\u003eBetter access to investors\u003c\/li\u003e\n\u003cli\u003eFaster partnership formation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynlogic’s Broad Pipeline and Big Partnerships Strengthen Its Rare-Disease Play\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSynlogic, Inc.'s strength is its 5 clinical-stage programs, which spread risk beyond one asset. Two Phase II PKU candidates, SYNB1618 and SYNB1934, give the platform two shots in the same rare-disease market. Its Roche and Ginkgo partnerships, plus a Cambridge base, add technical depth, hiring access, and credibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline breadth\u003c\/td\u003e\n\u003ctd\u003e5 clinical-stage programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePKU focus\u003c\/td\u003e\n\u003ctd\u003e2 Phase II candidates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing profile\u003c\/td\u003e\n\u003ctd\u003e4 oral, non-systemic programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic support\u003c\/td\u003e\n\u003ctd\u003eRoche and Ginkgo partnerships\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Synlogic, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Synlogic, Inc. SWOT snapshot to simplify biotech strategy reviews and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources for Synlogic assumptions to speed due diligence and let buyers verify each key claim via clear, traceable references.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSynlogic remains a clinical-stage biopharmaceutical company, with 0 approved or marketed products and 0 product revenue. That leaves the business dependent on pipeline milestones, trial data, and regulatory wins rather than sales. Until it secures FDA approval, the equity value rests on development progress, not recurring commercial cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e5 programs still in trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSynlogic, Inc.'s five named assets are still only in Phase I or Phase II, so none has cleared the main clinical and regulatory risk points yet. Early-stage biotech is highly binary: industry data show only about 10% to 15% of drug candidates entering Phase I reach approval, even after strong preclinical work. That leaves Synlogic, Inc.'s pipeline exposed to setback risk, long timelines, and high capital needs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1 oncology asset in Phase I\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSynlogic, Inc.’s only oncology asset, SYNB1891, is still in Phase I for solid tumors and lymphoma, so human data remain very limited. Phase I is the first-in-human stage and usually enrolls small cohorts, which means safety and early activity signals can still change fast. In oncology, the need to prove safety, efficacy, and delivery at once makes execution risk high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e4 rare-disease indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic’s weakness is its narrow portfolio: phenylketonuria, homocystinuria, enteric hyperoxaluria, and oncology. That small set of 4 rare-disease and cancer bets limits near-term market breadth, so each readout carries outsized weight. One trial miss can materially damage the story and investor confidence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnly 4 key indications\u003c\/li\u003e\n\u003cli\u003eLow near-term market breadth\u003c\/li\u003e\n\u003cli\u003eEach trial has outsized impact\u003c\/li\u003e\n\u003cli\u003eOne setback can move the stock\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic, Inc.’s partner dependence is a real weakness because its profile includes external ties with Roche and Ginkgo, so key resources and technology support sit partly outside its control. If either partner shifts priorities, Synlogic could see delays, weaker support, or a changed development path. Smaller biotech firms usually have less say in partner-led programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoche and Ginkgo ties add execution risk\u003c\/li\u003e\n\u003cli\u003ePartner shifts can slow development\u003c\/li\u003e\n\u003cli\u003eLess control means less flexibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynlogic’s Biggest Weakness: No Revenue, Early Pipeline, Heavy Partner Dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSynlogic’s biggest weakness is that it still has 0 approved products and 0 product revenue, so it depends on trial data and funding, not sales. Its five named assets remain only in Phase I\/II, where approval odds are roughly 10%–15%, and its 4-indication focus leaves little room for a miss. Partner ties with Roche and Ginkgo also cut control.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial base\u003c\/td\u003e\n\u003ctd\u003e0 approved, 0 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline stage\u003c\/td\u003e\n\u003ctd\u003e5 assets, Phase I\/II\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortfolio breadth\u003c\/td\u003e\n\u003ctd\u003e4 core indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner dependence\u003c\/td\u003e\n\u003ctd\u003eRoche, Ginkgo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSynlogic, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is taken directly from the full report and unlocks the complete, editable version once you buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePKU Phase II readouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1618 and SYNB1934 are both in Phase II for phenylketonuria, a rare disease that affects about 1 in 23,000 U.S. newborns. If readouts are positive, they could drive a sharp value re-rating because clinical proof in a well-defined orphan market would de-risk the synthetic biotic platform and support work in other metabolic disorders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-in-class oral biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSynlogic's oral, non-systemic biology could stand out versus injected or systemic drugs, especially for gut-driven metabolic diseases where local activity matters. Rare diseases are a strong fit: the EU defines them as affecting fewer than 1 in 2,000 people, so even modest efficacy can be meaningful when options are scarce. If human data show durable benefit and good tolerability, this could open a new treatment class.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHomocystinuria expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1353 for homocystinuria could add a second rare metabolic disease to Synlogic, broadening the reach beyond PKU. Homocystinuria affects about 1 in 200,000 to 1 in 335,000 births, so even a small label can expand the addressable pool. If it succeeds, the biomarker-led path using plasma homocysteine could also speed development and de-risk the program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnteric hyperoxaluria market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSYNB8802’s Phase I program for enteric hyperoxaluria can tap a rare, underserved market; the disease affects about 2% to 3% of recurrent calcium oxalate stone patients, and there are few targeted options. If early data show oxalate lowering, Synlogic, Inc. could open a new niche and widen its platform beyond amino-acid metabolism into kidney-stone biology.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I asset with orphan-like need\u003c\/li\u003e\n\u003cli\u003eFew targeted treatments today\u003c\/li\u003e\n\u003cli\u003ePossible first-mover niche\u003c\/li\u003e\n\u003cli\u003eBroader platform beyond metabolism\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology platform upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSYNB1891 is in Phase I for solid tumors and lymphoma, and oncology can be a much larger pool than rare-disease targets if the biology holds. Intratumoral delivery may keep immune activation local and reduce systemic exposure, which could improve tolerability. If the program works, it could lift Synlogic’s strategic value far beyond its current niche.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I: solid tumors and lymphoma\u003c\/li\u003e\n\u003cli\u003eLocal delivery may limit systemic exposure\u003c\/li\u003e\n\u003cli\u003eOncology offers bigger market upside\u003c\/li\u003e\n\u003cli\u003eSuccess could re-rate strategic value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynlogic’s Rare-Disease Pipeline Could Unlock Major Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSynlogic’s biggest upside is proof in rare, biomarker-led diseases: PKU, homocystinuria, and enteric hyperoxaluria. Phase II PKU assets can de-risk the platform, while SYNB1353 and SYNB8802 could expand the addressable rare-disease base. SYNB1891 adds oncology upside, where Phase I success could reset valuation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eUpside\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePKU\u003c\/td\u003e\n\u003ctd\u003ePhase II proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1353\u003c\/td\u003e\n\u003ctd\u003eSecond rare disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB8802\u003c\/td\u003e\n\u003ctd\u003eNew kidney niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1891\u003c\/td\u003e\n\u003ctd\u003eOncology expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 Phase II failure risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1618 and SYNB1934 are still unproven in Phase II, so any weak readout could hit Synlogic, Inc. hard. PKU trials must show real clinical benefit, not just biomarker shifts, or the market may discount the platform. A late-stage miss would likely weaken the pipeline story and investor confidence fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1 Phase I oncology uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1891 is still in Phase I, where oncology programs often hit dose-limiting toxicity, weak efficacy, or delivery problems. Solid tumors and lymphoma are crowded and biologically complex, so even promising early signals often fail to reach Phase II or Phase III. That makes the risk of never advancing the asset very high, and Synlogic, Inc. has limited room to absorb a setback.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive rare-disease therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePKU, homocystinuria, and hyperoxaluria all face active drug competition, and PKU alone affects about 1 in 23,000 U.S. births, so rivals can still take share in small orphan markets.\u003c\/p\u003e\n\u003cp\u003eWith FDA-approved options and late-stage candidates, new therapies can set a high bar on efficacy, safety, and dosing convenience, leaving little room for a weak profile.\u003c\/p\u003e\n\u003cp\u003eIn rare diseases, even modest rivalry can squeeze pricing and make payer access harder, which can cut Synlogic, Inc.'s peak revenue even if the mechanism is different.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFunding and dilution risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic, Inc. faced a classic clinical-stage biotech risk: it needed outside capital to keep trials moving, while investor appetite for pre-revenue names can dry up fast. When funding gets tight, new equity often comes at a steep discount and dilutes current holders. Limited cash can also force slower trial work, fewer programs, or a wind-down.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOngoing trial funding is expensive.\u003c\/li\u003e\n\u003cli\u003eWeak markets raise dilution risk.\u003c\/li\u003e\n\u003cli\u003eLess cash can delay milestones.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner execution risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic’s partner risk is high because its pipeline depends on two key outside relationships, Roche and Ginkgo Bioworks. If either partner shifts strategy, slows execution, or changes priorities, development timelines can slip and Synlogic can lose control over program pace and scope.\u003c\/p\u003e\n\u003cp\u003eThat dependence matters because external collaborators add science and scale, but they also add one more decision layer. In a two-partner setup, even one disruption can delay milestones, raise costs, or narrow future deal options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eTwo key partners increase execution dependence.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePartner delays can push clinical timelines back.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eStrategy changes can reduce Synlogic’s optionality.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynlogic Faces High Clinical, Competitive, and Funding Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSynlogic, Inc. still faces high clinical risk: SYNB1618 and SYNB1934 are only in Phase II, and SYNB1891 is in Phase I, so one weak readout could hurt the whole story. Competition is real in PKU, homocystinuria, and hyperoxaluria; PKU affects about 1 in 23,000 U.S. births, but payer and safety pressure can still cap sales. Cash and partner dependence add more risk, and any funding or collaborator slip can delay milestones.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical failure\u003c\/td\u003e\n\u003ctd\u003ePhase I-II\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket rivalry\u003c\/td\u003e\n\u003ctd\u003ePKU 1\/23,000 births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding strain\u003c\/td\u003e\n\u003ctd\u003eOngoing trial burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235045286153,"sku":"sybx-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sybx-swot-analysis.webp?v=1785733039","url":"https:\/\/dcfanalyst.com\/products\/sybx-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}